Why the study?
Does LMWH reduce the incidence of DVT, PE, and adverse events compared to UFH in patients with venous thromboembolism?
Meta-Analysis (n=2,045)
Does LMWH reduce the incidence of DVT, PE, and adverse events compared to UFH in patients with venous thromboembolism?
LMWH offers significant clinical advantages over UFH for venous thromboembolism, including reductions in mortality, bleeding, and thrombocytopenia.
Until a few years ago unfractionated heparin (UFH) was the standard treatment for venous thromboembolism (VTE). The introduction of LMWHs with their unique properties conferred a number of important advantages including greater activity against factor Xa, predictable anticoagulant response, better bioavailability, longer half-life, reduced binding to plasma proteins and macrophages, reduced effects on platelets and less bleeding. A recent meta-analysis of 16 randomised trials in 2045 patients compared the effects of LMWH and UFH on the incidence of deep vein thrombosis (DVT) and pulmonary embolism (PE). There was a reduction in mortality, bleeding and the incidence of thrombocytopenia in patients treated with LMWH.
No takes yet. Share an insight, caveat, or question.
V V Kakkar (2002) conducted a meta-analysis in Venous thromboembolism (n=2,045). Low molecular weight heparin (LMWH) vs. Unfractionated heparin (UFH) was evaluated on Incidence of deep vein thrombosis (DVT) and pulmonary embolism (PE).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: